Cantargia publishes year end report for 2017
Cantargia AB’s (”Cantargia”) year end report for 2017 is now available on the company’s web page www.cantargia.com/en/investors/financial-reportsSignificant events in the fourth quarter In October the first results from the CANFOUR clinical study of the first three patients in the first dose group were published. No serious side effects were documented and the first patient, who had then been treated on three occasions with the CAN04 antibody, had thus formally completed the safety evaluation in accordance with the clinical protocol. In October Cantargia received formal patent